Literature DB >> 11245987

The human ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3): promoter characterization and genomic structure.

A Navarro-Sabaté1, A Manzano, L Riera, J L Rosa, F Ventura, R Bartrons.   

Abstract

A DNA fragment containing 1.5 kb of the 5'-flanking region of the human ubiquitous PFKFB3 gene, coding for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, was cloned and its promoter activity was examined. The 5' flanking region contains a TATA box-like and GC-rich sequences, yielding several potential Specific protein (Sp-1) and activator protein (AP)-2 binding sites. Putative regulatory motifs for E-box, nuclear factor (NF)-1 and progesterone response element were also found by computer assisted analysis. Transient expression assays of truncated promoter-reporter constructs in HeLa cells showed that this gene is induced by phorbol esters (PDB) and cyclic-AMP-dependent protein kinase signal activation. Furthermore, the genomic organization of the PFKFB3 gene is reported. This gene spans more than 26 kb containing at least 16 exons that accounts for the two reported isoforms, inducible and ubiquitous, generated through alternative splicing of exon 15.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245987     DOI: 10.1016/s0378-1119(00)00591-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

Review 1.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis.

Authors:  Mark H Rider; Luc Bertrand; Didier Vertommen; Paul A Michels; Guy G Rousseau; Louis Hue
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

2.  Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect.

Authors:  Alexander Minchenko; Irene Leshchinsky; Irina Opentanova; Nianli Sang; Vickram Srinivas; Valerie Armstead; Jaime Caro
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

3.  Cooperation of adenosine with macrophage Toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene.

Authors:  Almudena Ruiz-García; Eva Monsalve; Laura Novellasdemunt; Aurea Navarro-Sabaté; Anna Manzano; Samuel Rivero; Antonio Castrillo; Marta Casado; Jorge Laborda; Ramón Bartrons; María José M Díaz-Guerra
Journal:  J Biol Chem       Date:  2011-04-04       Impact factor: 5.157

Review 4.  Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux.

Authors:  Brandon C Jones; Paula R Pohlmann; Robert Clarke; Surojeet Sengupta
Journal:  Cancer Metastasis Rev       Date:  2022-04-14       Impact factor: 9.237

5.  Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.

Authors:  Jason Chesney; Jennifer Clark; Alden C Klarer; Yoannis Imbert-Fernandez; Andrew N Lane; Sucheta Telang
Journal:  Oncotarget       Date:  2014-08-30

Review 6.  Cerebral Gluconeogenesis and Diseases.

Authors:  James Yip; Xiaokun Geng; Jiamei Shen; Yuchuan Ding
Journal:  Front Pharmacol       Date:  2017-01-04       Impact factor: 5.810

Review 7.  Fructose 2,6-Bisphosphate in Cancer Cell Metabolism.

Authors:  Ramon Bartrons; Helga Simon-Molas; Ana Rodríguez-García; Esther Castaño; Àurea Navarro-Sabaté; Anna Manzano; Ubaldo E Martinez-Outschoorn
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

8.  Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism.

Authors:  Susana Ros; Almut Schulze
Journal:  Cancer Metab       Date:  2013-02-04

9.  The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer.

Authors:  Luo Lu; Yaoyu Chen; Yu Zhu
Journal:  Oncotarget       Date:  2017-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.